Success Metrics

Active Trials
12(75%)

Phase Distribution

Ph phase_2
2
13%
Ph phase_3
1
6%
Ph phase_1
12
75%

Phase Distribution

12

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
12(80.0%)
Phase 2Efficacy & side effects
2(13.3%)
Phase 3Large-scale testing
1(6.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

12

trials recruiting

Total Trials

16

all time

Status Distribution
Active(15)
Other(1)

Detailed Status

Recruiting11
Not yet recruiting3
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
12
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 112 (80.0%)
Phase 22 (13.3%)
Phase 31 (6.7%)

Trials by Status

not_yet_recruiting319%
active_not_recruiting16%
recruiting1169%
unknown16%

Recent Activity

12 active trials
Showing 5 of 16
recruitingphase_3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312
not_yet_recruitingphase_2

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

NCT06930352
unknown

Expanded Access to Ziftomenib

NCT05738538
recruitingphase_1

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

NCT06448013
recruitingphase_1

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

NCT05848687
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07007312Phase 3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Recruiting
NCT06930352Phase 2

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Not Yet Recruiting
NCT05738538

Expanded Access to Ziftomenib

Unknown
NCT06448013Phase 1

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Recruiting
NCT05848687Phase 1

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Recruiting
NCT07623616Phase 2

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Recruiting
NCT07411586Phase 1

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

Not Yet Recruiting
NCT04067336Phase 1

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Active Not Recruiting
NCT06001788Phase 1

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
NCT06440135Phase 1

Ziftomenib Maintenance Post Allo-HCT

Recruiting
NCT05735184Phase 1

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Recruiting
NCT06769490Phase 1

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Recruiting
NCT06655246Phase 1

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Recruiting
NCT06397027Phase 1

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Recruiting
NCT07355335Phase 1

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Not Yet Recruiting
NCT06376162Phase 1

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Recruiting

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16